Skip to main content
Premium Trial:

Request an Annual Quote

GeneLink's Q1 Revenues Fall 45 Percent

NEW YORK (GenomeWeb News) – Consumer genomics firm GeneLink reported that its first-quarter revenues dropped 45 percent year over year following the sale of its GeneWize Life Sciences subsidiary.

For the three months ended March 31, the Orlando, Fla.-based company posted $771,664 in revenues, down from $1.4 million a year ago, it said in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

The company said that it closed the sale of GeneWize to Capsalus in February for $500,000 and a monthly earn-out provision for five years, which will provide GeneLink between $1.5 million and $4.5 million depending on GeneWize revenues. It said in the quarterly statement that it recognized a book gain of $759,054 from the sale of GeneWize.

GeneLink also inked a licensing and distribution deal with Gene Elite for certain skin care and nutrition product technologies, resulting in a payout of $1.5 million to GeneLink, of which $1 million was received in 2011 and $500,000 was received in February, the company said in its SEC document.

During the first quarter, GeneLink's R&D costs rose 82 percent year over year to $16,437 from $9,024 a year ago, and SG&A costs dropped 14 percent to $1.2 million from $1.4 million.

The company's net loss for the quarter was $105,673, or break-even on a per-share basis, compared to a net loss of $592,223, or break-even on a per-share basis, in Q1 2011. The company used more than 204.9 million shares in calculating its per-share figure in the recent quarter, compared to more than 157.1 million shares in the year-ago period.

GeneLink ended the quarter with $635,540 in cash and cash equivalents.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.